These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 26021142)
1. [Treatment of dyslipidemias with statins in primary and seconary prevention]. Janin A Rev Med Suisse; 2015 Apr; 11(468):787-8. PubMed ID: 26021142 [No Abstract] [Full Text] [Related]
2. [Statins in the management of dyslipidemias]. Scheen AJ Rev Prat; 2011 Oct; 61(8):1120-6. PubMed ID: 22135981 [TBL] [Abstract][Full Text] [Related]
3. Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma. Aronow WS J Am Geriatr Soc; 2009 Oct; 57(10):1942-3; author reply 1943-4. PubMed ID: 19807799 [No Abstract] [Full Text] [Related]
4. What is the role of statins in the elderly population? Stavropoulos K; Imprialos K; Doumas M; Athyros VG Expert Rev Clin Pharmacol; 2018 Apr; 11(4):329-331. PubMed ID: 29431524 [No Abstract] [Full Text] [Related]
5. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Virani SS Tex Heart Inst J; 2013; 40(3):288-9. PubMed ID: 23914021 [No Abstract] [Full Text] [Related]
6. Emerging clinical challenges in the use of statins. Hennekens CH; Breuer NR; Gelb IJ; Bjorkman DJ; Borer JS; Pfeffer MA Am J Med; 2013 Aug; 126(8):663-4. PubMed ID: 23786669 [No Abstract] [Full Text] [Related]
7. Statins: have we found the Holy Grail? Jeger R; Dieterle T Swiss Med Wkly; 2012; 142():w13515. PubMed ID: 22315166 [TBL] [Abstract][Full Text] [Related]
8. Starting statins for primary prevention of cardiovascular disease. Tunstall-Pedoe H Heart; 2013 Nov; 99(21):1547-8. PubMed ID: 23878178 [No Abstract] [Full Text] [Related]
11. [Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study]. González-Juanatey JR; Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC Rev Esp Cardiol; 2011 Apr; 64(4):286-94. PubMed ID: 21411216 [TBL] [Abstract][Full Text] [Related]
12. [Response by Prof. F. Mach]. Mach F Rev Med Suisse; 2015 Apr; 11(468):789. PubMed ID: 26021144 [No Abstract] [Full Text] [Related]
13. [Response by Prof N. Rodondi]. Rodondi N Rev Med Suisse; 2015 Apr; 11(468):788. PubMed ID: 26021143 [No Abstract] [Full Text] [Related]
14. Evaluation of the impact of the recent controversy over statins in France: the EVANS study. Saib A; Sabbah L; Perdrix L; Blanchard D; Danchin N; Puymirat E Arch Cardiovasc Dis; 2013 Oct; 106(10):511-6. PubMed ID: 24080324 [TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Lardizabal JA; Deedwania P Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102 [TBL] [Abstract][Full Text] [Related]
16. [Statin treatment in primary and secondary prevention--a statement]. Mach F; Riesen WF; Rodondi N; Von Eckardstein A Rev Med Suisse; 2014 Dec; 10(455):2430-3. PubMed ID: 25752015 [TBL] [Abstract][Full Text] [Related]
17. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy. Jialal I; Smith G Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574 [No Abstract] [Full Text] [Related]
18. Statins for primary prevention of cardiovascular disease. Majeed A BMJ; 2014 May; 348():g3491. PubMed ID: 24868092 [No Abstract] [Full Text] [Related]
19. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship? Shah PK Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083 [TBL] [Abstract][Full Text] [Related]